Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- Ann: Race releases complete cardio-protection data & video
Yes to an extent as the price that will ultimately be able to be...
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.41 |
Change
-0.055(3.77%) |
Mkt cap ! $236.2M |
Open | High | Low | Value | Volume |
$1.45 | $1.45 | $1.40 | $157.9K | 111.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3980 | $1.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.41 | 2613 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3980 | 1.400 |
1 | 3440 | 1.395 |
1 | 2500 | 1.380 |
2 | 1100 | 1.360 |
1 | 1534 | 1.350 |
Price($) | Vol. | No. |
---|---|---|
1.410 | 2613 | 2 |
1.440 | 24 | 1 |
1.445 | 319 | 2 |
1.450 | 699 | 2 |
1.455 | 24 | 1 |
Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.40 |
  |
Change
-0.055 ( 2.23 %) |
|||
Open | High | Low | Volume | ||
$1.44 | $1.44 | $1.40 | 6146 | ||
Last updated 15.46pm 28/05/2024 ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online